Immunotherapy in HIV disease: recent developments and future directions

Adjuvant immunotherapy, directly targeting the immune system, has been proposed as approach to modulate the immune response in HIV-infected subjects treated with HAART and without immune reconstitution. Most studies have been performed on Interleukin-2 (IL-2), focusing on immunological advantage of IL-2+HAART versus HAART alone in different stages of HIV infection. Preliminary results of two Phase III international studies, SILCAAT and ESPRIT, confirm a significant difference in CD4+ cells count, but underline that this immunological advantage does not reduce the rate of opportunistic infections and death. The authors do not provide any data of IL-2 driven immune reconstitution and this could be a bias in the interpretation of the results. Interleukin-7 (IL-7) Phase I studies are ongoing: the potential interest of IL-7 in the treatment of HIV-infection is based on its crucial role on T cell homeostasis both in thymic output and peripheral T proliferation and survival; despite SILCAAT and ESPRIT data, these studies are continuing. Finally, recently approved new class drugs, CCR5-antagonists, open a new scenario in HAART era: published results confirm an immune reconstitution better than other antiretroviral drugs.
Keywords: Immune reconstitution; Interleukin-2; Interleukin-7; CCR5-antagonists.

Articolo presente in – HAART and correlated pathologies n. 2

Download del’articolo download_pdf

golden goose outlet online golden goose femme pas cher fjallraven kanken backpack sale fjallraven kanken rugzak kopen fjällräven kånken reppu netistä fjallraven kanken táska Golden Goose Tenisice Hrvatska Basket Golden Goose Homme Golden Goose Sneakers Online Bestellen Kanken Backpack On Sale Fjallraven Kanken Mini Rugzak Fjällräven Kånken Mini Reppu Fjallraven Kanken Hátizsák nike air max 270 schuhe neue nike air schuhe nike schuhe damen 2019